Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | ATM Q654Rfs*10 |
| Gene Variant Detail | |
| Relevant Treatment Approaches | Olaparib |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| ATM Q654Rfs*10 | invasive bladder transitional cell carcinoma | predicted - sensitive | Talazoparib | Case Reports/Case Series | Actionable | In a clinical case study, Talzenna (talazoparib) treatment resulted in a complete response in a patient with metastatic muscle-invasive urothelial carcinoma harboring ATM Q654Rfs*10 (reported as Q654fs*10), along with BRCA2 K3326* and CHEK2 R145Q (PMID: 38638285). | 38638285 |